Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.

Loong, Herbert H; Wong, Carlos K H; Leung, Linda K S; Chan, Catherine P K; Chang, Andrea; Zhou, Zheng-Yi; Xie, Jipan; Gibbs, Meaghan

Loong, Herbert H; Wong, Carlos K H; Leung, Linda K S; Chan, Catherine P K; Chang, Andrea; Zhou, Zheng-Yi; Xie, Jipan; Gibbs, Meaghan.

Afiliação

Loong HH; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China. h_loong@clo.cuhk.edu.hk.
Wong CKH; Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, China.
Leung LKS; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Chan CPK; Novartis Pharmaceuticals Corporation, Hong Kong, China.
Chang A; Novartis Pharmaceuticals Corporation, Hong Kong, China.
Zhou ZY; Analysis Group, Inc, London, UK.
Xie J; Analysis Group, Inc, Los Angeles, CA, USA.
Gibbs M; Novartis Pharmaceuticals Corporation, Dubai, United Arab Emirates.

Cost Eff Resour Alloc ; 18(1): 50, 2020 Nov 07.

Article em En | MEDLINE | ID: mdl-33292314

Palavras-chave

Advanced non-small cell lung cancer; Anaplastic lymphoma kinase-positive; Ceritinib; cost-effectiveness; Hong kong

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Financiamentos_gastos Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Cost Eff Resour Alloc Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google